Ali Raif İlaç Wins Major Award

Ali Raif Pharmaceuticals, which has been dedicated for 58 years to protecting and improving human health by providing high-quality services and products to society, won first place in the 'Pharmaceutical Company with Most Brands in R&D Center' category within the 9th International Pharmaceutical Chemistry Congress R&D Awards.

Ali Raif, which has been conducting research and development activities for years, earned the status of R&D Center with the approval of the Turkish Ministry of Industry and Technology on 2 January 2017 and continues its operations.

Under the scope of the Turkey R&D 250 Research conducted by Turkishtime, the company, which ranks among the top positions in both project and brand rankings in its sector and has achieved 70 percent women researcher employment with its differentiated R&D team, was deemed worthy of first place in the 'Pharmaceutical Company with Most Brands in R&D Center' category within the 9th International Pharmaceutical Chemistry Congress R&D Awards held in Antalya on 8-11 April 2021.

Ali Raif Pharmaceuticals aims to develop innovative products that provide efficacy and differentiated pharmaceutical formulations for both patients and physicians, enhancing ease of use and improving patient compliance in the therapeutic areas in which it operates. With its mission of adding life value, the company prioritizes introducing new alternatives in its therapeutic areas to improve treatment success and expand its patent and brand portfolio.